Cerdulatinib
≥99%
- Product Code: 100006
CAS:
1198300-79-6
| Molecular Weight: | 445.54 g./mol | Molecular Formula: | C₂₀H₂₇N₇O₃S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8℃ |
Product Description:
Cerdulatinib is primarily used in the treatment of certain types of cancers, particularly those involving B-cell and T-cell malignancies. It functions as a dual inhibitor of SYK and JAK kinases, which are critical in the signaling pathways that promote cancer cell survival and proliferation. This makes it a potential therapeutic option for patients with relapsed or refractory hematologic cancers, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its ability to target multiple pathways simultaneously offers a promising approach for overcoming resistance to single-target therapies. Clinical trials are ongoing to further evaluate its efficacy and safety in various cancer types.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Light Yellow Brown Solid |
| Purity (%) | 98.5-100 |
| Infrared Spectrum | Conforms To Structure |
| NMR | Conforms To Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | Ft74,233.60 |
+
-
|
| 0.010 | 10-20 days | Ft121,316.46 |
+
-
|
| 0.025 | 10-20 days | Ft273,877.83 |
+
-
|
Cerdulatinib
Cerdulatinib is primarily used in the treatment of certain types of cancers, particularly those involving B-cell and T-cell malignancies. It functions as a dual inhibitor of SYK and JAK kinases, which are critical in the signaling pathways that promote cancer cell survival and proliferation. This makes it a potential therapeutic option for patients with relapsed or refractory hematologic cancers, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its ability to target multiple pathways simultaneously offers a promising approach for overcoming resistance to single-target therapies. Clinical trials are ongoing to further evaluate its efficacy and safety in various cancer types.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
Ft0.00
Ft0.00
Total :